SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharma earmarks capex of Rs 720 crore for FY19

04 Jun 2018 Evaluate

In order to complete existing projects, Alembic Pharmaceuticals has earmarked a capital expenditure of Rs 720 crore for FY19. The company had spent about Rs 600 crore of capex in the last fiscal year.

The pharma firm has filed 12 ANDAs (abbreviated new drug applications) during the March quarter, taking the total filings in FY18 to 26.

The company has six formulation and three API manufacturing facilities. It manufactures general oral solids in Panelav near Vadodara, Gujarat, and is in the process of putting up oncology oral solids and oncology injectable facilities at the same location.

Alembic Pharma Share Price

767.30 3.75 (0.49%)
22-Apr-2026 12:32 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1659.60
Dr. Reddys Lab 1220.85
Cipla 1234.10
Zydus Lifesciences 930.85
Lupin 2309.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×